Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:1764218rdf:typepubmed:Citationlld:pubmed
pubmed-article:1764218lifeskim:mentionsumls-concept:C0034693lld:lifeskim
pubmed-article:1764218lifeskim:mentionsumls-concept:C0442027lld:lifeskim
pubmed-article:1764218lifeskim:mentionsumls-concept:C0034262lld:lifeskim
pubmed-article:1764218lifeskim:mentionsumls-concept:C0600688lld:lifeskim
pubmed-article:1764218pubmed:issue3lld:pubmed
pubmed-article:1764218pubmed:dateCreated1992-2-18lld:pubmed
pubmed-article:1764218pubmed:abstractTextThis study evaluated the oral toxicity of pyridostigmine bromide in Sprague-Dawley rats when administered for 13 weeks by daily gavage. Groups of 10 rats/sex received doses of 0, 5, 15, 30, or 60 mg/kg/day. Toxicity was limited to exaggerated cholinergic stimulation at doses of 15 mg/kg/day or greater. Significant findings included tremors and inhibition of RBC acetylcholinesterase. Thus, 5 mg/kg/day of pyridostigmine bromide appears to be the no observed toxic effect level under the conditions of the present investigation.lld:pubmed
pubmed-article:1764218pubmed:languageenglld:pubmed
pubmed-article:1764218pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1764218pubmed:citationSubsetIMlld:pubmed
pubmed-article:1764218pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:1764218pubmed:statusMEDLINElld:pubmed
pubmed-article:1764218pubmed:monthSeplld:pubmed
pubmed-article:1764218pubmed:issn0895-3988lld:pubmed
pubmed-article:1764218pubmed:authorpubmed-author:ChungHHlld:pubmed
pubmed-article:1764218pubmed:authorpubmed-author:LevineB SBSlld:pubmed
pubmed-article:1764218pubmed:authorpubmed-author:LongRRlld:pubmed
pubmed-article:1764218pubmed:issnTypePrintlld:pubmed
pubmed-article:1764218pubmed:volume4lld:pubmed
pubmed-article:1764218pubmed:ownerNLMlld:pubmed
pubmed-article:1764218pubmed:authorsCompleteYlld:pubmed
pubmed-article:1764218pubmed:pagination283-9lld:pubmed
pubmed-article:1764218pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:1764218pubmed:meshHeadingpubmed-meshheading:1764218-...lld:pubmed
pubmed-article:1764218pubmed:meshHeadingpubmed-meshheading:1764218-...lld:pubmed
pubmed-article:1764218pubmed:meshHeadingpubmed-meshheading:1764218-...lld:pubmed
pubmed-article:1764218pubmed:meshHeadingpubmed-meshheading:1764218-...lld:pubmed
pubmed-article:1764218pubmed:meshHeadingpubmed-meshheading:1764218-...lld:pubmed
pubmed-article:1764218pubmed:meshHeadingpubmed-meshheading:1764218-...lld:pubmed
pubmed-article:1764218pubmed:meshHeadingpubmed-meshheading:1764218-...lld:pubmed
pubmed-article:1764218pubmed:meshHeadingpubmed-meshheading:1764218-...lld:pubmed
pubmed-article:1764218pubmed:meshHeadingpubmed-meshheading:1764218-...lld:pubmed
pubmed-article:1764218pubmed:meshHeadingpubmed-meshheading:1764218-...lld:pubmed
pubmed-article:1764218pubmed:meshHeadingpubmed-meshheading:1764218-...lld:pubmed
pubmed-article:1764218pubmed:meshHeadingpubmed-meshheading:1764218-...lld:pubmed
pubmed-article:1764218pubmed:year1991lld:pubmed
pubmed-article:1764218pubmed:articleTitleSubchronic oral toxicity of pyridostigmine bromide in rats.lld:pubmed
pubmed-article:1764218pubmed:affiliationDepartment of Pharmacology, University of Illinois, Chicago 60680.lld:pubmed
pubmed-article:1764218pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:1764218pubmed:publicationTypeResearch Support, U.S. Gov't, Non-P.H.S.lld:pubmed